Navigation Links
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
Date:6/11/2008

- RECIST-defined objective response supports expansion of Simon 2-Stage

designed trial -

BRANFORD, Conn., June 11 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Phase II Trial evaluating CR011-vcMMAE for the treatment of patients with unresectable Stage III or Stage IV melanoma has met the efficacy criteria for advancement to the second stage of enrollment. Of the first six evaluable patients in this Phase II trial one patient has had a confirmed objective response, as measured by RECIST criteria. As part of the Simon 2-Stage design the trial will now expand to enroll a total of 32 patients.

"We are very encouraged by the emerging clinical efficacy of CR011-vcMMAE. We believe that this objective response confirms the initial activity observed in the Phase I trial, the results of which were reported earlier this month at ASCO," commented Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen Corporation. "This trial is enrolling well, and we expect the data to quickly mature allowing us to provide further updates from the study later in the second half of this year."

Dr. Ronit Simantov, Vice President and Chief Medical Officer commented, "There remains a substantial unmet need for patients with advanced melanoma. As we continue to evaluate CR011-vcMMAE 1.88 mg/kg given once every three weeks in this ongoing Phase II trial, we are also looking to further optimize the activity of CR011-vcMMAE by actively exploring alternative dosing schedules including more frequent intravenous administration of this novel agent."

This ongoing open-label, multi-center Phase II study e
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Cord Blood America, Inc. ( ... or the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, ... today, and provides an update for shareholders detailing why a ... requested. Dear Shareholders, As we reflect ...
(Date:1/23/2015)... 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a ... cytokine adsorber to reduce deadly inflammation in critically-ill ... $385,642, net of transaction costs, in non-dilutive funding ... Tax Certificate Transfer Program sponsored by the New ...
(Date:1/23/2015)... Ala. , Jan. 23, 2015 Gem Pharmaceuticals ... patients have been enrolled into the Company,s Phase 2 ... and safety of Gem,s lead compound, GPX-150 (an investigational ... advanced or metastatic disease. Logo - ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... , , ... 2009 Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced ... trial in patients chronically infected with the hepatitis C virus (HCV). The ... antiviral effect of clemizole monotherapy in the absence of interferon. ...
... , , LYON, France ... the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and ... submitted to the U.S. Food and Drug Administration (FDA) a ... vaccine. Responding to recent recommendations by the FDA, the company,s ...
Cached Medicine Technology:Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial 2Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial 3Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA 2Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA 3
(Date:1/22/2015)... The City of West Hollywood hosted a news conference on ... anniversary of the Supreme Court decision Roe v. Wade, which legalized ... the Roe vs. Wade decision and the fight to protect a ... City of West Hollywood Councilmember Abbe Land. “We need to continue ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, ... Health Alliance (PPHA). The PPHA's passion for others' well-being ... NFL greats, treated for obstructive sleep apnea (OSA) has propelled ... cause in the valley. The most recent plans for an ...
(Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... Jude scientist honored , , MEMPHIS, Tenn., June 16 ... in the Pathology Department at St. Jude Children,s Research Hospital, ... Sciences. , , Selected by The Pew Charitable Trusts ... scientists, Mullighan will receive a $240,000 award over four years ...
... , NIXA, Mo., June 16 The National Autism Association ... charge to qualifying couples who have a child with autism. ... divorce within the autism community, the NAA,s Family First Program ... need of marriage counseling. Now the organization is providing tools ...
... -- Duke University engineers have taken a first ... by combining chemotherapy with heat administered from the end ... it should be technically possible to treat brain tumors ... of surgery, systemic chemotherapy or radiation. The bioengineers ...
... and the Association of Medicine and the Person are collaborating ... . The peer-reviewed, international journal is aimed at medical ... field of ethics and quality of life. The first ... The Journal of Medicine and the Person ...
... of organizations representing healthcare stakeholders throughout Greater Boston ... Foundation (RWJF) to participate in a planning grant ... Quality (AF4Q) initiative. AF4Q is the Foundation,s signature ... in targeted communities, reduce racial and ethnic disparities, ...
... ... ... , , ,Who: ,Dr. Jeffrey Sturchio, Chairman, Corporate Council on Africa, ... Office of the U.S. Global AIDS Coordinator, U.S. Department of State ,Dr. Kate Tulenko, ...
Cached Medicine News:Health News:St. Jude Scientist Named Pew Scholar 2Health News:St. Jude Scientist Named Pew Scholar 3Health News:National Autism Association's Family First Program Now Providing Free Tools to Help Combat Autism Divorce Rates 2Health News:Potential for noninvasive brain tumor treatment 2Health News:Springer to publish Journal of Medicine and the Person 2Health News:Greater Boston unites to transform health care 2Health News:Building Healthcare Leadership in Africa: A Call to Action 2
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium....
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches....
7 mm flattened hook. Flat serrated handle with polished finish. Overall length: 4.9 inches....
Left angled 5 mm blunt hook. Overall length: 9.9 inches....
Medicine Products: